In conclusion, this study identified R3HDM4 as a novel oncogenic driver in KIRC, with roles including promoting tumor proliferation and metastasis through EMT regulation, modulating TME composition and immune checkpoint expression, correlating with TMB/MSI and ICI response, and predicting sensitivity to MEK/ERK inhibitors. The gene discussed is MAP2K7; the disease is neoplasm.